Category Archives: Business and Investments

Latest From Business and Investments

Biotech IPO Window – Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue to drop and investors shy away from risk. This is the fifth IPO withdrawal since June. Ambit, Agendia and Clarus cited market reasons for their withdrawals, and Advanced BioHealing sought a higher valuation exit via acquisition. Only one biotech IPO, Horizon Pharma, has made it out in the last six months. Of the nine biotech IPOs so far in 2011, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Policies that Benefit Start-Ups Grow the Bio-Economy

lab

The United States remains the land of entrepreneurialism despite our lingering economic troubles. To maintain our nation’s global leadership and drive job growth, we must continue to create policies that encourage and reward innovation in growth industries — including biotechnology. Jeffrey Bussgang, a general partner at the venture capital firm Flybridge Capital Partners contributed an interesting piece to Fortune/CNN Money in which he points out that start-up companies – not small businesses – are the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BioWorld previews BIO India: India Emerges as Global Player via Multinational Partnering

BioWorld’s Tom Wall interviewed BIO’s Alan Eisenberg (subscription required) on what attendees can expect at this week’s BIO India International Partnering Conference. Interest in India has been strong and attendance at the conference is expected to surpass last year’s event. The population forecasted to grow in the coming years, combined with significant disease burden is a draw for many companies seeking business development and partnering opportunities. BIO India will feature keynote speakers Glenn Saldanha, Chairman Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

The Burrill Report: Pushing Policies in a Changed Washington

The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the financial markets and the impact on public policy. Eisenberg discusses implementation of BIO’s legislative proposals and the outlook for the industry. BIO will be hosting the BIO Investor Forum to bring together industry leaders to discuss these recent developments that could have a major influence in helping to shape the future of biotechnology.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum Company Snapshot: Syndax Pharmaceuticals

Syndax

Next up in our Company Snapshot segment for the BIO Investor Forum is another presenting company of the event. Hear from Joanna Horobin, President & CEO of Syndax Pharmaceuticals, Inc. Company Snapshot What are the short-term and long-term priorities for your company? Near-term we are focused on moving our lead product candidate, entinostat, in to a phase 3 clinical trial for post-menopausal women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Long-term our goal is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,